

Brian K Kaspar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8327136/publications.pdf>

Version: 2024-02-01

46
papers

6,951
citations

186265
28
h-index

223800
46
g-index

48
all docs

48
docs citations

48
times ranked

9790
citing authors

#	ARTICLE	IF	CITATIONS
1	AAV9-MCT8 Delivery at Juvenile Stage Ameliorates Neurological and Behavioral Deficits in a Mouse Model of MCT8-Deficiency. <i>Thyroid</i> , 2022, 32, 849-859.	4.5	14
2	Neurotoxic Astrocytes Directly Converted from Sporadic and Familial ALS Patient Fibroblasts Reveal Signature Diversities and miR-146a Theragnostic Potential in Specific Subtypes. <i>Cells</i> , 2022, 11, 1186.	4.1	11
3	Conditional deletion of SMN in cell culture identifies functional SMN alleles. <i>Human Molecular Genetics</i> , 2021, 29, 3477-3492.	2.9	9
4	Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 497-507.	4.1	13
5	Voluntary wheel running with and without follistatin overexpression improves NMJ transmission but not motor unit loss in late life of C57BL/6J mice. <i>Neurobiology of Aging</i> , 2021, 101, 285-296.	3.1	5
6	Follistatin-induced muscle hypertrophy in aged mice improves neuromuscular junction innervation and function. <i>Neurobiology of Aging</i> , 2021, 104, 32-41.	3.1	11
7	Sox11 is an Activity-Regulated Gene with Dentate-Gyrus-Specific Expression Upon General Neural Activation. <i>Cerebral Cortex</i> , 2020, 30, 3731-3743.	2.9	7
8	Ibuprofen enhances synaptic function and neural progenitors proliferation markers and improves neuropathology and motor coordination in Machado-Joseph disease models. <i>Human Molecular Genetics</i> , 2019, 28, 3691-3703.	2.9	21
9	Mutations in glycyl-tRNA synthetase impair mitochondrial metabolism in neurons. <i>Human Molecular Genetics</i> , 2018, 27, 2187-2204.	2.9	26
10	Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 12, 75-88.	5.1	33
11	MiR-155 deletion reduces ischemia-induced paralysis in an aortic aneurysm repair mouse model: Utility of immunohistochemistry and histopathology in understanding etiology of spinal cord paralysis. <i>Annals of Diagnostic Pathology</i> , 2018, 36, 12-20.	1.3	22
12	Glia-neuron interactions in neurological diseases: Testing non-cell autonomy in a dish. <i>Brain Research</i> , 2017, 1656, 27-39.	2.2	30
13	Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. <i>Molecular Therapy</i> , 2017, 25, 870-879.	8.2	84
14	NEUROD1 Instructs Neuronal Conversion in Non-Reactive Astrocytes. <i>Stem Cell Reports</i> , 2017, 8, 1506-1515.	4.8	106
15	High content analysis in amyotrophic lateral sclerosis. <i>Molecular and Cellular Neurosciences</i> , 2017, 80, 180-191.	2.2	10
16	Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. <i>New England Journal of Medicine</i> , 2017, 377, 1713-1722.	27.0	1,642
17	HSPB1 mutations causing hereditary neuropathy in humans disrupt non-cell autonomous protection of motor neurons. <i>Experimental Neurology</i> , 2017, 297, 101-109.	4.1	18
18	SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits. <i>Nature Communications</i> , 2017, 8, 16063.	12.8	106

#	ARTICLE	IF	CITATIONS
19	The C9orf72 protein interacts with Rab1a and the <sc>ULK</sc>1 complex to regulate initiation of autophagy. EMBO Journal, 2016, 35, 1656-1676.	7.8	327
20	rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System. Molecular Therapy, 2016, 24, 1030-1041.	8.2	18
21	Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6496-E6505.	7.1	139
22	Adeno Associated Virus 9-Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice. Thyroid, 2016, 26, 1311-1319.	4.5	34
23	Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16046.	4.1	34
24	An NF- κ B - EphrinA5-Dependent Communication between NC2+ Interstitial Cells and Myoblasts Promotes Muscle Growth in Neonates. Developmental Cell, 2016, 36, 215-224.	7.0	33
25	Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis. Nature Medicine, 2016, 22, 397-403.	30.7	112
26	Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy. Journal of Neuromuscular Diseases, 2015, 2, 185-192.	2.6	34
27	Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model. Science Advances, 2015, 1, e1500078.	10.3	33
28	Chronic Oligodendrogenesis and Remyelination after Spinal Cord Injury in Mice and Rats. Journal of Neuroscience, 2015, 35, 1274-1290.	3.6	138
29	Macrophage Migration Inhibitory Factor as a Chaperone Inhibiting Accumulation of Misfolded SOD1. Neuron, 2015, 86, 218-232.	8.1	98
30	Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6993-7002.	7.1	165
31	Transplantation of cerebellar neural stem cells improves motor coordination and neuropathology in Machado-Joseph disease mice. Brain, 2015, 138, 320-335.	7.6	78
32	A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy. Molecular Therapy, 2015, 23, 192-201.	8.2	193
33	Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose-response Study in Mice and Nonhuman Primates. Molecular Therapy, 2015, 23, 477-487.	8.2	217
34	AAV1.NT-3 Gene Therapy for Charcot-Marie-Tooth Neuropathy. Molecular Therapy, 2014, 22, 511-521.	8.2	86
35	Making Sense of Pain: Are Pluripotent Stem Cell-derived Sensory Neurons a New Tool for Studying Pain Mechanisms?. Molecular Therapy, 2014, 22, 1403-1405.	8.2	6
36	Electrophysiological biomarkers in spinal muscular atrophy: proof of concept. Annals of Clinical and Translational Neurology, 2014, 1, 34-44.	3.7	55

#	ARTICLE	IF	CITATIONS
37	Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APP ^{swe} PSEN1 ^{dE9} mouse model for Alzheimer's disease. <i>Neurobiology of Disease</i> , 2014, 62, 31-43.	4.4	5
38	Delayed Disease Onset and Extended Survival in the SOD1 ^{G93A} Rat Model of Amyotrophic Lateral Sclerosis after Suppression of Mutant SOD1 in the Motor Cortex. <i>Journal of Neuroscience</i> , 2014, 34, 15587-15600.	3.6	116
39	Microglia Induce Motor Neuron Death via the Classical NF- κ B Pathway in Amyotrophic Lateral Sclerosis. <i>Neuron</i> , 2014, 81, 1009-1023.	8.1	527
40	Intravenous Injections in Neonatal Mice. <i>Journal of Visualized Experiments</i> , 2014, , e52037.	0.3	41
41	Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS. <i>Molecular Therapy</i> , 2013, 21, 2148-2159.	8.2	178
42	Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. <i>Nature Biotechnology</i> , 2011, 29, 824-828.	17.5	696
43	Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. <i>Nature Biotechnology</i> , 2009, 27, 59-65.	17.5	1,157
44	Mesenchymal Stem Cells as Trojan Horses for GDNF Delivery in ALS. <i>Molecular Therapy</i> , 2008, 16, 1905-1906.	8.2	15
45	Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19546-19551.	7.1	140
46	Virus ^Δ delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2005, 57, 773-776.	5.3	108